Mecanismos celulares distintos subyacen al bloqueo de los puntos de control anti-CTLA-4 y anti-PD-1
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.El bloqueo del punto de control inmune, incluidas las terapias anti-CTLA-4 y anti-PD-1, se dirige a subconjuntos específicos de células T en tumores. Estas terapias activan distintos mecanismos de células inmunes, lo que lleva al rechazo del tumor a través de diferentes vías.
Área De La Ciencia
- Inmunología
- Investigación del cáncer
- Biología de las células T
Sus Antecedentes
- El bloqueo del punto de control inmune (ICB) ofrece respuestas duraderas en algunos pacientes con cáncer.
- La comprensión de los mecanismos de anti-CTLA-4 y anti-PD-1 en el rechazo tumoral es limitada.
Objetivo Del Estudio
- Para perfilar exhaustivamente los efectos de la ICB en los infiltrados inmunes del tumor.
- Para aclarar los distintos mecanismos celulares de las terapias anti-CTLA-4 y anti-PD-1.
Principales Métodos
- Se utilizó la citometría de masa para analizar los infiltrados inmunológicos del tumor.
- Se estudiaron modelos de melanoma en humanos y tumores en ratones.
Principales Resultados
- El ICB se dirige a subconjuntos específicos de células T que se infiltran en el tumor.
- El anti-PD-1 expande los subconjuntos de células T CD8 de tipo agotado.
- El anti-CTLA-4 expande las células efectoras CD4 de tipo ICOS+ Th1 y las células T CD8 específicas de tipo agotado.
Conclusiones
- Los anti-CTLA-4 y los anti-PD-1 activan mecanismos celulares distintos para el rechazo del tumor.
- Los hallazgos proporcionan información sobre la heterogeneidad de la respuesta ICB.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...